Stifel upgraded eFFECTOR Therapeutics (NASDAQ:EFTR) to “buy” from “hold” and raised its price target to $7 from $1.30, saying the “zotatifin combo is emerging as an active and underappreciated asset in breast cancer.”...
Stifel upgraded IDEADYA Biosciences (NASDAQ:IDYA) to “buy” from “hold” and raised its price target to $24 from $18 following additional darovasertib data in uveal melanoma, which revealed an improved mPFS in first-line...
Stifel launched coverage of Disc Medicine (NASDAQ:IRON) with a “buy” rating and $37 price target. The stock closed at $28.10, up $2.34, on April 20. “Our positive thesis is predicated on optimism for the company’s lead...
Stifel initiated coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and $24 price target. The stock closed at $7.35 on March 15. Theseus is a clinical-stage, small molecule oncology company that...
Stifel launched coverage of Mineralys Therapeutics (NASDAQ:MLYS) with a “buy” rating and 12-month price target of $45. The stock closed at $18.96 on March 7. Mineralys’ lorundrostat is targeting hyperaldosteronism, a...
Stifel initiated coverage of Compass Therapeutics (NASDAQ:CMPX) with a “buy” rating and price target of $9. The stock closed at $3.95 on Jan. 26. “We believe the recent presentation at ASCO-GI 2023 of updated results...
Stifel upgraded Sight Sciences (NASDAQ:SGHT) to “buy” from “ hold” and raised its price target to $15 from $10 after a survey of 41 minimally invasive glaucoma surgery (MIGS)-trained ophthalmologists “gives us increased...
Stifel launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and $12 price target. The stock closed at $2.61 on Nov. 25. Analyst Stephen Willey writes that OmniAb represents the construction of a high-throughput...
Stifel downgraded PhaseBio Pharmaceuticals (NASDAQ:PHAS) to “hold” from “buy” and slashed its price target to $1 from $15, citing an ownership dispute over PhaseBio’s bentracimab, a potential ticagrelor reversal agent...
Stifel downgraded IDEAYA Biosciences (NASDAQ:IDYA) to “hold” from “buy” and reduced its price target to $13 from $16 “on the belief that it’s difficult to gain high conviction in the MTAP/MAT2A thesis (we ascribe...